---
title: "Antidepressant Maintenance vs Active Monitoring After Remission: Decision Analysis by Relapse Risk"
id: "medrxiv-21-antidepressant-maintenance-versus-active-monitoring-after-depression-remission"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-21-antidepressant-maintenance-versus-active-monitoring-after-depression-remission"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.17.26358340v1?rss=1"
published_at: "2026-07-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Antidepressant Maintenance vs Active Monitoring After Remission: Decision Analysis by Relapse Risk
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-21-antidepressant-maintenance-versus-active-monitoring-after-depression-remission
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.17.26358340v1?rss=1)
- **Published At:** 2026-07-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This decision-analytic study compared **continuous antidepressant maintenance** with **discontinuation plus active monitoring** after remission from major depressive disorder (MDD). - An individual-level health-state transition model was developed with a 5-year horizon and calibrated to randomized maintenance-discontinuation trials and a longitudinal first-episode cohort. - The clinical setting modeled was an outpatient decision after completing an 8-month continuation phase following remission from MDD. - Participants were represented across four relapse-risk strata, from very low risk (first mild episode) to high risk (highly recurrent depression). - Primary outcomes included severity-weighted **depression-months**, **antidepressant medication-years**, medication-years per depression-month averted, and net benefit across patient preference thresholds. - Continuous maintenance reduced overall depression burden but required substantially greater cumulative medication exposure; the tradeoff depended strongly on baseline relapse risk. - Efficiency (medication-years per depression-month averted) ranged across risk strata from a median of 11.8 (95% UI, 7.8–19.6) in the very low-risk group to 1.5 (95% UI, 0.8–3.0) in the high-risk group. - Applying preference thresholds (the max extra medication-years a patient would accept to avert one depression-month) altered the preferred strategy: at 3 medication-years per depression-month averted, maintenance was preferred for moderate- and high-risk patients; at 2, only for high-risk patients; at 1, no risk group favored maintenance. - The authors conclude that the value of continuous maintenance depends on both baseline relapse risk and patient preferences regarding long-term medication exposure, and that the model provides a quantitative framework to support shared decision-making. - This report is a preprint and has not been peer reviewed; competing interests and funding sources are declared in the source.
## Clinical Analysis & Structured Key Points
Skip to main content HOMESUBMITFAQBLOGALERTS / RSSRESOURCESABOUT Search for this keyword Advanced Search Follow this preprint Antidepressant Maintenance Versus Active Monitoring After Depression Remission: A Decision Analysis Stratified by Relapse Risk and Patient Preferences View ORCID Profile William U Meyerson, View ORCID Profile Tianxi Cai, View ORCID Profile Jordan W Smoller doi: https://doi.org/10.64898/2026.07.17.26358340 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. AbstractInfo/HistoryMetrics Preview PDF Abstract Importance: Patients who achieve remission from major depressive disorder (MDD) often face a preference-sensitive decision between continued antidepressant maintenance and discontinuation with active monitoring. Quantifying the tradeoff between depression burden and long-term medication exposure may support more individualized shared decision-making. Objective: To quantify tradeoffs between continuous antidepressant maintenance and active monitoring after MDD remission, and to identify preference thresholds favoring each strategy across relapse-risk strata. Design: Individual-level decision-analytic health-state transition model calibrated to randomized maintenance-discontinuation trials and a longitudinal first depressive episode cohort, with a 5-year time horizon. Setting: Outpatient clinical decision after completion of an 8-month continuation phase following remission from MDD. Participants: Adults in remission from MDD, represented across 4 clinically anchored relapse-risk strata ranging from very low risk after a first mild episode to high risk after highly recurrent depression. Exposures: Continuous antidepressant maintenance vs discontinuation with active monitoring and antidepressant restart after detected relapse. Main Outcomes and Measures: Severity-weighted depression-months, antidepressant medication-years, medication-years per depression-month averted, and net benefit across preference thresholds defined as the maximum additional medication-years a patient would be willing to accept to avert 1 depression-month. Results: Continuous maintenance reduced depression burden but required substantially more medication exposure, with efficiency strongly dependent on relapse risk. Medication-years per depression-month averted ranged from 11.8 (95% uncertainty interval [UI], 7.8-19.6) in the very low-risk group to 1.5 (95% UI, 0.8-3.0) in the high-risk group. At a preference threshold of 3 medication-years per depression-month averted, maintenance was preferred for moderate- and high-risk patients; at a threshold of 2, only for high-risk patients; and at a threshold of 1, for no risk group. Conclusions and Relevance: In this decision-analytic model, the value of continuous antidepressant maintenance depended strongly on baseline relapse risk and patient preferences regarding long-term medication exposure. These findings provide a quantitative framework for shared decision-making about antidepressant maintenance after remission from MDD. Competing Interest Statement Dr. Smoller is a member of the Scientific Advisory Board of Sensorium Therapeutics (with options), has received consulting fees from Tempus, Inc., and has received grant support from Biogen, Inc. Dr. Meyerson reports no financial relationships with commercial interests. Dr. Cai reports no financial relationships with commercial interests. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study used only aggregate estimates reported in previously published articles and supplementary materials, all of which were publicly available before study initiation and are linked in the reference list. No individual-level human participant data were accessed or analyzed. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes FUNDER INFORMATION DECLARED National Institutes of Health, https://ror.org/01cwqze88, T15LM007092 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. bioRxiv and medRxiv thank the following for their generous financial support: The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. Donate to openRxiv Back to top Previous Next Posted July 20, 2026. Download PDF Print/Save Options Author Declarations Supplementary Material Data/Code Email Share Citation Tools Get QR code Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos Subject Areas All Articles Addiction Medicine Allergy and Immunology Anesthesia Cardiovascular Medicine Dentistry and Oral Medicine Dermatology Emergency Medicine Endocrinology (including Diabetes Mellitus and Metabolic Disease) Epidemiology Forensic Medicine Gastroenterology Genetic and Genomic Medicine Geriatric Medicine Health Economics Health Informatics Health Policy Health Systems and Quality Improvement Hematology HIV/AIDS Infectious Diseases (except HIV/AIDS) Intensive Care and Critical Care Medicine Medical Education Medical Ethics Nephrology Neurology Nursing Nutrition Obstetrics and Gynecology Occupational and Environmental Health Oncology Ophthalmology Orthopedics Otolaryngology Pain Medicine Palliative Medicine Pathology Pediatrics Pharmacology and Therapeutics Primary Care Research Psychiatry and Clinical Psychology Public and Global Health Radiology and Imaging Rehabilitation Medicine and Physical Therapy Respiratory Medicine Rheumatology Sexual and Reproductive Health Sports Medicine Surgery Toxicology Transplantation Urology Evaluation/discussion of this paper x 0 0 0 0 0 0 We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more
## Related Clinical Research

- [Depression plus Diabetes: Increased Mortality and Complication Risks — Systematic Review and Meta-](https://medichelpline.com/clinical-feed/pubmed-42693777.md) (DOI: 10.1017/S2045796026100882)
- [Atomoxetine and Stimulant Use in Pregnancy: Maternal and Birth Outcome Findings](https://medichelpline.com/clinical-feed/womens-mental-health-0-atomoxetine-and-stimulants-during-pregnancy-what-do-we-know-about-pregnancy.md)
- [Depression and Long-Term HbA1c Variability Linked to Higher Cardiovascular‑Renal Risk in Type 2 Di](https://medichelpline.com/clinical-feed/pubmed-42671118.md) (DOI: 10.1002/dmrr.70222)
- [Metformin for Pain: Protocol for a Systematic Review of Safety and Efficacy](https://medichelpline.com/clinical-feed/bmj-open-12-safety-and-efficacy-of-metformin-for-the-treatment-of-pain-protocol-for-a.md)
- [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.